GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Egetis Therapeutics AB (OSTO:PLED BTA) » Definitions » Gross-Profit-to-Asset %

Egetis Therapeutics AB (OSTO:PLED BTA) Gross-Profit-to-Asset % : 1.69% (As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Egetis Therapeutics AB Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Egetis Therapeutics AB's annualized Gross Profit for the quarter that ended in Mar. 2025 was kr12.80 Mil. Egetis Therapeutics AB's average Total Assets over the quarter that ended in Mar. 2025 was kr758.20 Mil. Therefore, Egetis Therapeutics AB's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 was 1.69%.


Egetis Therapeutics AB Gross-Profit-to-Asset % Historical Data

The historical data trend for Egetis Therapeutics AB's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egetis Therapeutics AB Gross-Profit-to-Asset % Chart

Egetis Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -29.28 -9.06 -21.25 7.05 4.44

Egetis Therapeutics AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.20 6.42 3.73 4.96 1.69

Competitive Comparison of Egetis Therapeutics AB's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Egetis Therapeutics AB's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egetis Therapeutics AB's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Gross-Profit-to-Asset % falls into.


;
;

Egetis Therapeutics AB Gross-Profit-to-Asset % Calculation

Egetis Therapeutics AB's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=34.5/( (760.2+792.3)/ 2 )
=34.5/776.25
=4.44 %

Egetis Therapeutics AB's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2025 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2025 )/( (Total Assets (Q: Dec. 2024 )+Total Assets (Q: Mar. 2025 ))/ count )
=12.8/( (792.3+724.1)/ 2 )
=12.8/758.2
=1.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2025) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Egetis Therapeutics AB Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Egetis Therapeutics AB's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Egetis Therapeutics AB Business Description

Traded in Other Exchanges
Address
Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.

Egetis Therapeutics AB Headlines

No Headlines